Fidursi 120 mg/2,4 ml AND 500 mg/10 ml Concentrate for solution for infusion
PDF Leaflet Revision Date: 13 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including MIBC, NSCLC, SCLC, HCC, BTC, and GC/GEJC.
Dosage (summary)
IV infusion over 60 mins; varies by indication, e.g., 1500 mg every 4 weeks for NSCLC.
Special Populations
- Elderly (u2265 65 years)
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding during treatment and for 3 months after.
Key Drug Interactions
- No significant drug-drug interactions identified
Contraindications
- Hypersensitivity to durvalumab or excipients
Common side effects
- Cough
- Diarrhoea
- Rash
Counselling Points
- Monitor for immune-mediated reactions
- Avoid pregnancy during treatment
- Inform about potential side effects
Serious warnings
- Immune-mediated pneumonitis
- Hepatitis
- Colitis
- Endocrinopathies
Important Disclaimer
The Fidursi 120 mg/2,4 ml AND 500 mg/10 ml Concentrate for solution for infusion professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
